# ANCILLARY STUDY OF THE ADOPTION AND SUSTAINABILITY OF ED-INITIATED BUPRENORPHINE (CTN-0079-A-1). DSC5 CONTRACT. 09/20/2019 - 02/28/2021. N01DA-19-2250.

> **NIH NIH N01** · THE EMMES COMPANY, LLC · 2020 · $237,062

## Abstract

ANCILLARY STUDY OF THE ADOPTION AND SUSTAINABILITY OF ED-INITIATED BUPRENORPHINE (CTN-0079-A-1)

## Key facts

- **NIH application ID:** 10265981
- **Project number:** 75N95019D00013-P00001-759501900089-1
- **Recipient organization:** THE EMMES COMPANY, LLC
- **Principal Investigator:** PAUL VANVELDHUISEN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $237,062
- **Award type:** —
- **Project period:** 2019-09-20 → 2021-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10265981

## Citation

> US National Institutes of Health, RePORTER application 10265981, ANCILLARY STUDY OF THE ADOPTION AND SUSTAINABILITY OF ED-INITIATED BUPRENORPHINE (CTN-0079-A-1). DSC5 CONTRACT. 09/20/2019 - 02/28/2021. N01DA-19-2250. (75N95019D00013-P00001-759501900089-1). Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/grant/nih/10265981. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*